Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

3 Months Ended

Sep. 30, 2021

Notes Tables

Schedule of Stockholders Equity [Table Text Block]

										Accumulated
					Additional					Other
	Common Stock				Paid-in		Retained			Comprehensive			Non-Controlling
	Shares		Amount		Capital		Earnings			Income(Loss)			Interest			Total
Balances at June 30, 2021		38,955	$	390	$	534,411	$	1,085,461		$	(57,291	)	$	8,263		$	1,571,234
Net earnings								69,615						(634	)		68,981
Other comprehensive income											(6,925	)		(39	)		(6,964	)
Common stock issued for exercise of options		295		3		36,345		(13,481	)								22,867
Common stock issued for restricted stock awards		20		0		0		(9,765	)								(9,765	)
Cash dividends								(12,493	)								(12,493	)
Stock-based compensation expense						11,396											11,396
Common stock issued to employee stock purchase plan		3		0		1,358											1,358
Employee stock purchase plan expense						341											341
Balances at September 30, 2021		39,273	$	393	$	583,851	$	1,119,337		$	(64,216	)	$	7,590		$	1,646,955

										Accumulated
					Additional					Other
	Common Stock				Paid-in		Retained			Comprehensive
	Shares		Amount		Capital		Earnings			Income(Loss)			Total
Balances at June 30, 2020		38,453	$	385	$	420,536	$	1,057,470		$	(97,199	)	$	1,381,192
Cumulative effect adjustments due to adoption of new accounting standards and other								(276	)					(276	)
Net earnings								33,395						33,395
Other comprehensive loss											14,057			14,057
Common stock issued for exercise of options		117		1		13,727								13,728
Common stock issued for restricted stock awards		25		0				(4,890	)					(4,890	)
Cash dividends								(12,336	)					(12,336	)
Stock-based compensation expense						12,667								12,667
Common stock issued to employee stock purchase plan		6		0		1,463								1,463
Employee stock purchase plan expense						286								286
Balances at September 30, 2020		38,601	$	386	$	448,679	$	1,073,362		$	(83,142	)	$	1,439,285

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Unrealized Gains (Losses) on Derivative Instruments			Foreign Currency Translation Adjustments			Total
Balance as of June 30, 2021	$	(6,193	)	$	(51,098	)	$	(57,291	)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne		84			(8,607	)		(8,523	)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)		1,598			-			1,598
Balance as of September 30, 2021(2)	$	(4,511	)	$	(59,705	)	$	(64,216	)

	Unrealized Gains (Losses) on Derivative Instruments			Foreign Currency Translation Adjustments			Total
Balance as of June 30, 2020	$	(13,253	)	$	(83,946	)	$	(97,199	)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne		11			11,914			11,925
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne (3)		2,132			-			2,132
Balance as of September 30, 2020(2)	$	(11,110	)	$	(72,032	)	$	(83,142	)